Cleerly Brings Advanced AI Heart Imaging to the American College of Cardiology's Chicago Community Health Fair
Cleerly will demonstrate its FDA-cleared heart image analyses using mobile scanners in collaboration with Corazon Imaging and Philips
CHICAGO, March 25, 2025--(BUSINESS WIRE)--Cleerly, a leader in AI imaging technology, is proud to support the American College of Cardiology's (ACC) Chicago Community Health Fair. This event will take place on Tuesday, March 25, from 3-7 p.m. CT at The Salvation Army Ray & Joan Kroc Corps Community Center.
Heart disease is the leading cause of death in the U.S. and worldwide. The event aims to promote heart health as an accessible and equitable resource for all community members. Attendees will learn about actionable strategies that can improve heart health, including guidance on exercise, healthy eating, and medical interventions. Additionally, the event will feature on-site heart screenings for blood pressure and heart murmurs, as well as informative sessions about heart disease.
In collaboration with local Chicago doctors and Corazon Imaging, Cleerly is providing advanced AI-Quantitative Coronary CT (AI-QCT) analyses for coronary atherosclerotic plaque to patients from the community. Coronary atherosclerotic plaque is a buildup within artery walls that narrows and restricts blood flow to the heart muscle and can lead to cardiovascular complications, including heart attacks. Local doctors will explain the findings to patients and advise them on actionable strategies that can improve heart health.
Just as mammograms are used for early cancer detection, Cleerly uses an AI-enabled platform to analyze advanced imaging to assist in the early identification of patients at higher risk for heart attacks. Along with receiving FDA clearance, Cleerly is also a covered service for Medicare, a status that requires robust clinical support and evidence.
"We understand what a clear diagnosis and a personalized treatment plan can do for someone's peace of mind and heart health, and we have made it our mission to identify at-risk individuals before a heart attack occurs," said James Min, MD, founder and CEO of Cleerly. "Along with our partners and the amazing doctors of Chicago, we are thrilled to bring Cleerly's AI-based Plaque and Ischemia software to the ACC's Chicago Community Health Fair."
"While Coronary CTA's role as a frontline tool to diagnose coronary artery disease has been a long time coming, it is absolutely here to stay. While initially valuable at determining coronary artery stenoses, CCTA has rapidly evolved to provide comprehensive information about plaque type, burden, and hemodynamic significance. Corazon has demonstrated this diagnostic pathway can be effectively translated to the community-based setting with over 8,000 CCTAs performed to date," said John Rumberger, PhD, MD, FACC, MSCCT, Medical Director and Director of Cardiac Imaging at Corazon Imaging.
"Philips is dedicated to providing better care for more people. With cardiovascular disease on the rise, the ability to bring wider access to high-quality cardiac care directly to communities can be impactful," said Melissa Howard, CT Business Leader, Philips North America. "Corazon Imaging's mobile CT unit, which will be at ACC's Chicago Community Health Fair, features the Philips CT 5100 Incisive. Using Philips' latest AI-enabled technology to get clear images with less radiation exposure means patients can get accurate diagnoses faster and with more confidence."
The Chicago Community Health Fair is part of the ACC's broader 2025 Annual Scientific Session, which will gather the global cardiovascular community in Chicago from March 29-31.
Learn More
Visit www.cleerlyhealth.com to learn more about Cleerly and find a provider near you. For additional information about coronary artery disease, visit our education page: https://cleerlyhealth.com/patient-education.
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325365245/en/
Contacts
Cleerly Media Contact Christy Sievertpress@cleerlyhealth.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau. Per the terms of the agreement, Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achievement of development, regulatory and sales milestones. Any royalties on global net sales in the future (outside the designated territories) would be in the low double digits. HS-20094 has been evaluated in over 1,000 patients and administered as a weekly subcutaneous injection. The candidate has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist. The candidate is currently being evaluated in a phase III study in obesity in China, and a phase IIb study in diabetes is ongoing. The in-licensing agreement for an obesity candidate will expand REGN's obesity pipeline, which includes trevogrumab. Regeneron recently announced positive interim results from the ongoing phase II COURAGE study investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity. COURAGE was designed to investigate the quality of weight loss in patients with obesity. Results showed that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass. Garetosmab is being evaluated for the treatment of fibrodysplasia ossificans progressive. The successful development of any obesity treatment will be a great boost for the company. We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi SNY reported results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD). While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same. REGN and SNY are currently reviewing the data and plan to discuss the next steps with regulatory authorities. Year to date, REGN's shares have lost 31.7% compared with the industry's 3.2% decline. Image Source: Zacks Investment Research Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line. Eylea sales have been under pressure for some time now due to competition from Roche's Vabysmo. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line. Apart from Eylea, profits from the sales of asthma drug Dupixent are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for Dupixent. While the obesity market is lucrative, REGN is a pretty late entrant here. The market is dominated by bigwigs like Novo Nordisk NVO and Eli Lilly LLY. The stupendous success of Novo Nordisk's obesity drug, Wegovy (semaglutide) and Eli Lilly's Zepbound has prompted many companies to join the bandwagon. Buoyed by this success, both Lilly and NVO have taken significant strides in developing their obesity portfolios further. Given the significant market potential of obesity, other players are also striving to grab a chunk of this pie. Regeneron currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Bloomberg
an hour ago
- Bloomberg
Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill
By and Steven T. Dennis Save Senate Republicans are considering cuts to Medicare spending to help pay for Donald Trump's signature legislative package. The GOP lawmakers are proceeding cautiously as they expand their search for savings to a popular health insurance program nearly all Americans rely upon in retirement, presenting the move as an effort to root out waste, fraud and abuse. That includes cutting payments to health insurance companies that run private Medicare plans.
The Hill
2 hours ago
- The Hill
Blue states call on FDA to expand abortion pill access
Attorneys general of New York, California, New Jersey and Massachusetts are asking the Food and Drug Administration (FDA) to expand access to the abortion pill and remove some 'unnecessary' drug restrictions that have been in place for more than two decades. The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers. The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000. Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home. Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions. The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported. More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy. 'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems. The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.' The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy. The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug. The FDA has yet to reply to a request for comment from The Hill about the petition.
